Pfizer Inc. (NYSE: PFE) shares rose 1.85% to close at $30.50 on October 30, 2026, gaining $0.55 from the previous close of $29.95. In after-hours trading, the stock declined $0.12, or 0.41%, to $30.38.
During the regular session, shares traded between $30.14 and $30.67, opening at $30.51. Trading volume reached approximately 27.62 million shares, below the average volume of 33.75 million. Pfizer’s intraday market capitalization stood at approximately $173.70 billion.
The company’s 52-week trading range was $23.62 to $30.67. Its beta was 0.28, while trailing earnings per share stood at $0.76 and the price-to-earnings ratio was 40.10. The one-year analyst target estimate was $29.26.
Company Overview
Founded in 1849 and headquartered in New York, Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, markets, distributes, and sells medicines and vaccines.
The company operates through three segments: Biopharma, PC1, and Pfizer Ignite. Its portfolio spans cardiovascular and metabolic medicines, migraine treatments, vaccines, infectious disease therapies, inflammation and immunology products, rare disease medicines, and oncology treatments.
Pfizer markets products under numerous brands, including Eliquis, Nurtec ODT, Vydura, Prevnar, Abrysvo, Nimenrix, Paxlovid, Xeljanz, Enbrel, Cibinqo, Litfulo, and Vyndaqel. Its oncology portfolio includes treatments across several cancer types, alongside biosimilars and sterile injectable medicines.
The company also maintains collaboration agreements with Bristol Myers Squibb, Astellas Pharma, Merck KGaA, and BioNTech, among others. Pfizer is also working with Bolt Biotherapeutics to develop biomolecular artificial intelligence foundation models.
Financial and Valuation Snapshot
Pfizer’s trailing earnings per share were reported at $0.76, with a price-to-earnings ratio of 40.10. Its market capitalization stood at approximately $173.70 billion.
The one-year analyst target estimate was $29.26, below the October 30 closing price of $30.50. The stock was also trading near the upper end of its 52-week range.
The company reported a forward annual dividend of $1.72 per share, representing a yield of 5.74%. The dividend announcement specified a cash payment of $0.43 per share, with an ex-dividend date of November 6, 2026.
Upcoming Earnings and Corporate Events
Pfizer’s third-quarter 2026 earnings report was scheduled for November 3, 2026. The release will provide investors with updated information on the company’s financial performance and business operations.
The dividend schedule includes an ex-dividend date of November 6, 2026, followed by a dividend payment date listed as December 7, 2026.
The supplied screenshots do not include the upcoming quarterly results or management’s updated guidance.
Market Outlook
Pfizer shares advanced during the October 30 session, closing near their reported 52-week high. The stock’s relatively low beta of 0.28 and forward dividend yield of 5.74% provide additional context for investors assessing its market profile.
The company’s broad pharmaceutical portfolio spans established medicines, vaccines, oncology treatments, and rare disease therapies. Its upcoming earnings report will offer an opportunity to evaluate recent operating performance and management commentary.
Investors will also be monitoring the announced dividend and the company’s ability to sustain its financial and shareholder-return commitments. The available market data does not establish whether the recent share-price increase reflects a change in expectations ahead of the earnings release.
